Nektar Therapeutics to Participate in Two Investor Conferences in March

Nektar Therapeutics (Nasdaq: NKTR) announced management will participate in two investor conferences in March 2026: TD Cowen 46th Annual Health Care Conference in Boston (March 2-4) and Jefferies Biotech on the Beach Summit in Miami (March 9-11).

Rhea-AI Summary

Nektar Therapeutics (Nasdaq: NKTR) announced management will participate in two investor conferences in March 2026: TD Cowen 46th Annual Health Care Conference in Boston (March 2-4) and Jefferies Biotech on the Beach Summit in Miami (March 9-11).

The TD Cowen presentation is webcast on Wednesday, March 4, 2026 at 9:10 a.m. ET with a replay available for 30 days; one-on-one meetings at Jefferies are available by request.

Argus Feb 25 session

+2.85% close to close Open Argus

Details

News Market Reaction – NKTR

On Feb 25, the first trading day after this news, NKTR closed 2.85% above the previous close.

Data tracked by StockTitan Argus for the Feb 25 session.

Market Context

This announcement focuses on Nektar’s participation in March investor conferences, offering further ...

Analysis

This announcement focuses on Nektar’s participation in March investor conferences, offering further visibility following recent REZOLVE‑AD Phase 2b data, sizeable equity offerings, and a new NKTR‑0165 collaboration. Investors may monitor how management frames Phase 3 plans, capital deployment from recent raises, and the broader pipeline narrative. Key items to watch include updates consistent with prior 8‑K and 424B5 disclosures and any refined timelines around rezpegaldesleukin’s Phase 3 program.

Key Figures

TD Cowen conference dates: March 2-4, 2026 Jefferies summit dates: March 9-11, 2026 Webcast time (ET): 9:10 a.m. Eastern Time +1 more

TD Cowen conference dates

March 2-4, 2026

TD Cowen 46th Annual Health Care Conference in Boston

Jefferies summit dates

March 9-11, 2026

2026 Jefferies Biotech on the Beach Summit in Miami

Webcast time (ET)

9:10 a.m. Eastern Time

Scheduled presentation at TD Cowen conference on March 4, 2026

Replay availability

30 days

Length of time conference presentation replay remains accessible

Historical Context

5 past events · Latest: Feb 17

5 events

1. Feb 17

   Research collaboration

   24h Move

   +3.5%

   Collaboration with UCSF to study NKTR-0165 in multiple sclerosis models.

2. Feb 13

   Offering closed

   24h Move

   +0.5%

   Closing of $460M public offering with underwriters’ option fully exercised.

3. Feb 11

   Offering priced

   24h Move

   +18.5%

   Pricing of upsized $400M public offering to fund rezpegaldesleukin Phase 3.

4. Feb 10

   Proposed offering

   24h Move

   +51.1%

   Announcement of proposed $300M public offering under effective S-3ASR shelf.

5. Feb 10

   Clinical data update

   24h Move

   +51.1%

   REZOLVE-AD Phase 2b data showing durable efficacy and favorable safety.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, Feb. 24, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be participating in the TD Cowen 46th Annual Health Care Conference taking place March 2-4, 2026 in Boston and the 2026 Jefferies Biotech on the Beach Summit taking place March 9-11, 2026 in Miami.

• TD Cowen 46th Annual Health Care Conference in Boston on Wednesday, March 4, 2026 – webcast of the presentation to be available at 9:10 a.m. Eastern Time / 6:10 a.m. Pacific Time – link here 
• 2026 Jefferies Biotech on the Beach Summit in Miami – March 9-11, 2026 – company management to be available for one-on-one meetings

The presentation will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. A replay of the presentation will be available for 30 days.

If you would like to request a one-on-one meeting with company management during the conferences, please reach out to your respective representative.

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in one Phase 2b clinical trial in atopic dermatitis, one Phase 2b clinical trial in alopecia areata, and one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.

Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.

For Investors:

Vivian Wu
628-895-0661
VWu@nektar.com

Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com 
212-915-2577

For Media:

Jonathan Pappas
LifeSci Communications
857-205-4403
jpappas@lifescicomms.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-therapeutics-to-participate-in-two-investor-conferences-in-march-302696266.html

SOURCE Nektar Therapeutics

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Nektar Therapeutics (NKTR) present at the TD Cowen conference in March 2026?

Nektar will present on Wednesday, March 4, 2026 at 9:10 a.m. ET. According to Nektar, the presentation will be webcast live and accessible via the investor events page and the provided webcast link.

How can investors watch Nektar Therapeutics (NKTR) webcast from the TD Cowen 46th Annual Health Care Conference?

Investors can watch the live webcast via the provided webcast link and the investor events page. According to Nektar, the presentation will be available live and a replay will be posted for 30 days after the event.

What are the dates for Nektar Therapeutics (NKTR) at the 2026 Jefferies Biotech on the Beach Summit?

Nektar management will attend the Jefferies summit March 9-11, 2026 in Miami. According to Nektar, company representatives will be available for one-on-one meetings during those dates by request.

How can investors request a one-on-one meeting with Nektar (NKTR) at the March 2026 conferences?

Request a one-on-one meeting through your conference representative or broker to coordinate schedules. According to Nektar, interested parties should reach out to their respective representative to request meetings with company management.

Will there be a replay of Nektar's (NKTR) TD Cowen presentation and for how long will it be available?

Yes, a replay will be available for 30 days after the live presentation. According to Nektar, the replay will be posted on the investor events section of the company's website for that 30-day period.

Where can I find Nektar Therapeutics (NKTR) presentation materials and the webcast link for March 2026 events?

Presentation materials and the webcast link are on the company's Investor Events page at https://ir.nektar.com/events-and-presentations/events. According to Nektar, the webcast and replay will be accessible via that investor events section.